Variational AI

Company profile

About Variational AI

Variational AI is a generative AI drug discovery company founded in 2019 and headquartered in Vancouver, Canada. The company has developed Enki™, a foundation model platform purpose-built for the earliest stages of small molecule drug discovery. Enki™ generates novel, synthesizable small molecules optimized across multiple parameters including potency, selectivity, ADMET properties, and synthetic feasibility. The platform is pre-trained on 760+ drug targets spanning kinases, GPCRs, proteases, oxidoreductases, hydrolases, ion channels, and other key target classes. By using generative AI to design compounds de novo rather than screening existing libraries, Variational AI enables pharmaceutical and biotech partners to explore uncharted regions of chemical space and discover first- and best-in-class compounds. The company's mission is to redefine the unit economics of drug discovery, enabling partners to bring novel therapeutics to patients faster and more cost-effectively. Enki™ simultaneously optimizes across 50+ parameters and can perform hyper-efficient lead optimization while constrained to defined scaffolds. The platform eliminates traditional hit identification and hit-to-lead phases, allowing R&D teams to move directly into lead optimization with higher-quality starting points. Variational AI's multidisciplinary team combines expertise in machine learning, medicinal chemistry, and computational chemistry, with AI scientists trained at institutions including MIT, Caltech, Berkeley, Google, Microsoft Research, and D-Wave Quantum. The company collaborates with pharmaceutical companies including Merck, and works across therapeutic areas from oncology to chronic inflammatory conditions.

Company description · Variational AI official website